NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News $90.56 -0.61 (-0.67%) As of 07/13/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PBE alerts:Sign Up Key Stats Today's Range$89.89▼$90.5650-Day Range$80.39▼$93.1852-Week Range$63.92▼$94.06Volume2,805 shsAverage Volume7,020 shsMarket Capitalization$282.55 millionAssets Under Management$284.43 millionDividend Yield1.70%Net Expense Ratio0.58%Aggregate RatingModerate Buy ETF Overview PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. Read More Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.56%0.57%0.51%0.53%Other Expenses0.08%0.47%0.55%0.58%0.55%Total Expense0.58%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.71%-0.64%-0.70%-0.62%Net Expense0.58%0.59%0.63%0.58%0.60% Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBE ETF News HeadlinesInvesco Biotechnology & Genome ETF declares quarterly distribution of $0.8106June 22, 2026 | msn.comInvesco Biotechnology & Genome ETF declares quarterly distribution of $0.0824March 24, 2026 | msn.comThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the absolute peak of the dot-com era. An MIT study found that 95% of companies investing in AI are seeing zero measurable return - yet the spending continues. OpenAI CEO Sam Altman has publicly said investors are 'overexcited' about AI. The investors who survived the dot-com crash weren't the ones who called the bottom - they were the ones who weren't fully exposed when it happened. Thor Metals Group offers a free guide on building a retirement not tied to this bet.July 14 at 1:00 AM | Thor Metals (Ad)Invesco Biotechnology & Genome ETF declares quarterly distribution of $0.4197December 22, 2025 | seekingalpha.comInvesco Nasdaq Biotechnology ETF declares quarterly distribution of $0.0958September 22, 2025 | msn.comInvesco Biotechnology & Genome ETF declares quarterly distribution of $0.2341September 22, 2025 | msn.comSee More Headlines PBE ETF - Frequently Asked Questions How have PBE shares performed this year? Invesco Biotechnology & Genome ETF's stock was trading at $82.15 at the start of the year. Since then, PBE shares have increased by 10.2% and is now trading at $90.56. Who are Invesco Biotechnology & Genome ETF's major shareholders? Top institutional shareholders of Invesco Biotechnology & Genome ETF include Dynamic Advisor Solutions LLC (0.17%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), NVIDIA (NVDA) and Bristol Myers Squibb (BMY). Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings30 Fund Statistics Assets Under Management$284.43 million Average Daily Volume$9.10 thousand Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume50 Put Options0 Call Options50 Short Interest3,592 shs Miscellaneous Outstanding Shares3,120,000Beta0.70 Creation Unit10,000 Creation Fee$500.00 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report Top 10 PBE HoldingsVertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 5.23%Amgen (NASDAQ:AMGN)Holding Weight: 4.78%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 4.75%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 4.69%Biogen (NASDAQ:BIIB)Holding Weight: 4.65%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 4.65%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.45%United Therapeutics (NASDAQ:UTHR)Holding Weight: 4.25%Bio-Techne (NASDAQ:TECH)Holding Weight: 3.51%Protagonist Therapeutics (NASDAQ:PTGX)Holding Weight: 3.35%Full Holdings DetailsPBE Sector ExposurePBE Industry Exposure This page (NYSEARCA:PBE) was last updated on 7/14/2026 by MarketBeat.com Staff. From Our PartnersSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredUnder $1 while the market panicsThe new deadline for crypto’s best bill, the Clarity Act, is August 7th. That's the Senate's final session day...Crypto 101 Media | SponsoredBNZI Lands a Zacks Upgrade!Banzai International (NASDAQ: BNZI) just received a Zacks Rank 2 (Buy) upgrade, driven by improving earnings e...Huge Alerts | SponsoredThey told you not to miss this oneThe largest companies in the SP 500 are now more overvalued relative to fundamentals than they were at the abs...Thor Metals | SponsoredThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
